These data highlighted key dysregulated genes shared across different cell types in BOS [28], that are also some of the most highly dysregulated genes in the AML-ASXL1 dataset, revealing potential biomarkers and therapeutic targets. This evidence concerns the gene ASXL1 and Buschke-Ollendorff syndrome.